Who is sponsoring NCT05513443?

NCT05513443 is sponsored by Karolinska Institutet.

What drugs are being tested in NCT05513443?

Interventions in NCT05513443: Irreversible electroporation, IRE, Radical prostatectomy, Radiation therapy.

What condition does NCT05513443 study?

NCT05513443 studies Prostate Cancer.

Is NCT05513443 still recruiting?

NCT05513443 is currently recruiting now. Last updated 20 January 2025.

Last reviewed 2025-01-20 · How we verify

NCT05513443: PRIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prostate Cancer IRE Study (PRIS)

Recruiting now NA Last updated 20 January 2025

What this trial tests

NA trial testing Irreversible electroporation, IRE in Prostate Cancer in 184 participants. Currently enrolling.

Timeline

1 September 2022

Primary endpoint
1 February 2026

1 September 2026

Quick facts

Lead sponsor	Karolinska Institutet
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	184
Start date	1 September 2022
Primary completion	1 February 2026
Estimated completion	1 September 2026
Sites	1 location across Sweden

Drugs / interventions tested

Irreversible electroporation, IRE
Radical prostatectomy
Radiation therapy — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Karolinska Institutet

Who can join

40 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the feasibility to treat localized prostate cancer diagnosed with MRI and targeted/systematic biopsies, with IRE in comparison with conventional radical treatments with the primary objective to locally control the tumour with a minimum of side effects.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

A narrative clinical trials review in the realm of focal therapy for localized prostate cancer.
Lazarovich A, Viswanath V, Dahmen AS, Sidana A. · · 2024 · cited 4× · PMID 39697719 · DOI 10.21037/tcr-23-2406
Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer.
Rodríguez-Sánchez L, Emberton M, de Reijke T, Stricker P, et al · · 2024 · cited 4× · PMID 37853538 · DOI 10.5534/wjmh.230160
Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer.
Lantz A, Nordlund P, Falagario U, Jäderling F, et al · · 2023 · cited 4× · PMID 37091033 · DOI 10.1016/j.euros.2023.03.003
Pulsed electric fields: a sharp sword in the battle against cancers.
Zhang L, Dong S, Teng F, Wang Y, et al · · 2025 · PMID 41357174 · DOI 10.3389/fimmu.2025.1682539

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Karolinska Institutet trials

Trials by the same sponsor.

NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05513443 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
Last refreshed: 20 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05513443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing